Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

US Patent 9315488 · Granted Apr 19, 2016

Estimated economic value: $348,384,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibi2024
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune 2024
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune 2024
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune 2024
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune 2024
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune 2024
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune 2024
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune 2024
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune 2024
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune 2024
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune 2023
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune 2023